The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Secretary of Education Betsy DeVos and her family have seen their investments skyrocket since President Donald Trump started enacting pro-business policies. Meanwhile, DeVos...Politicsread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
T-Mobile is choosing to move ahead with a merger with Sprint even though it will prop up Dish Network as a new, possibly disruptive fourth U.S. wireless competitor.Technologyread more
Danger is lurking in the stock market: An abrupt sell-off could be around the corner if the Federal Reserve doesn't deliver the rate cut the market expects next week, the firm...Marketsread more
Shares of Beyond Meat jumped nearly 10% Monday, nearing its all-time high, on investor optimism ahead of its earnings.Food & Beverageread more
Carl Icahn thinks Occidental Petroleum's CEO got played by the Oracle of Omaha himself in the company's effort to buy Anadarko Petroleum.Investingread more
The U.S. Food and Drug Administration has approved the first generic copies of a popular, pricey pill for nerve pain. The agency on Monday said it approved nine generic...Biotech and Pharmaceuticalsread more
Starbucks is licensing its mobile and loyalty program technology in a deal that will give global franchisees the chance to offer the Starbucks mobile app to customers.Restaurantsread more
Despite allegations against it, Valeant may still have some bright spots that could be attractive for investors, a senior analyst said on Friday.
"Its business is fundamentally strong," Irini Koffler, Mizuho Securities, told CNBC's "Closing Bell. "
"We think this company has a lot of optionality; they've got a great emerging markets business valued at about $2 billion that they could sell off under distress."
Koffler also said that the company's acquisitions, including Bausch & Lomb, are great assets that add to its value.
The Canadian drug company's stock price dropped 47 percent in October after short seller Citron Research accused it of improperly inflating its revenue. Valeant Chief Executive Officer Michael Pearson has denied the allegations, but on Wednesday, a U.S. Senate panel launched a bipartisan probe into pharmaceutical pricing, seeking documents from four drugmakers, including Valeant.
Valeant's plunge also pressured other pharmaceutical and health-care companies, and weighed on the entire sector.
Peter Andersen, of Congress Wealth Management, is a former lover of the stock and held it for about 2 1/2 years. He sold his holdings last week after a Valeant conference call.
"We just to need to wait a little bit more to get through this rolling disclosure," he said in the same interivew.
As the company continues to leak bad information, he said, investors should wait until it's over to get back into the stock. He also said it is difficult to put a value on certain segments of the business.
"I think it's quite toxic now; I don't think anyone would be looking at the company to buy one of its divisions," he added.
— Reuters contributed to this report.